Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1 | Zendy

Charles Kouanfack | Zendy; Mireille Mpoudi-Etame | Zendy; Pierrette Omgba Bassega | Zendy; Sabrina EymardDuvernay | Zendy; Sandrine Leroy | Zendy; Sylvie Boyer | Zendy; Martine Peeters | Zendy; Alexandra Calmy | Zendy; Éric Delaporte | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1

Author(s) -

Charles Kouanfack,

Mireille Mpoudi-Etame,

Pierrette Omgba Bassega,

Sabrina EymardDuvernay,

Sandrine Leroy,

Sylvie Boyer,

Martine Peeters,

Alexandra Calmy,

Éric Delaporte

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1904340

Subject(s) - dolutegravir , efavirenz , regimen , virology , medicine , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load

An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as EFV600) was the World Health Organization preferred first-line treatment for human immunodeficiency virus type 1 (HIV-1) infection until June 2018. Given concerns about side effects, dolutegravir-based and low-dose efavirenz-based combinations have been considered as first-line treatments for HIV-1 in resource-limited settings.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research